Physician profile
Robert G Eaker
NPI 1679518104
$2,546.96
in general payments reported to CMS, 2019-2025
19 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $310 · 2021: $412 · 2022: $430 · 2023: $420 · 2024: $305 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,075.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $627.81 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $334.17 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $81.36 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $64.87 | 2021-2023 | |
| Pfizer INC. | $53.44 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $49.59 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $35.13 | 2019-2021 | |
| Astellas Pharma US INC | $28.10 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $22.32 | 2021 | |
| Sanofi Pasteur INC. | $20.39 | 2023 | |
| Glaxosmithkline, LLC. | $16.67 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.56 | 2025 | Qelbree |
| Arbor Pharmaceuticals, INC. | $15.66 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $15.54 | 2024 | Cologuard Collection Kit |
| Melinta Therapeutics, LLC | $15.27 | 2019 | |
| Axsome Therapeutics, INC. | $13.71 | 2025 | Auvelity |
| Pacira Therapeutics, INC. | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Eaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.